249 related articles for article (PubMed ID: 17021762)
21. Immunohistochemical studies using monoclonal antibodies on lymph nodes from patients with mycosis fungoides and Sézary's syndrome.
Willemze R; Scheffer E; Meijer CJ
Am J Pathol; 1985 Jul; 120(1):46-54. PubMed ID: 3893151
[TBL] [Abstract][Full Text] [Related]
22. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma.
Wong HK
Discov Med; 2013 Sep; 16(87):71-8. PubMed ID: 23998443
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides.
Rasheed H; Tolba Fawzi MM; Abdel-Halim MR; Eissa AM; Mohammed Salem N; Mahfouz S
Am J Dermatopathol; 2010 Apr; 32(2):162-9. PubMed ID: 20051814
[TBL] [Abstract][Full Text] [Related]
24. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
[TBL] [Abstract][Full Text] [Related]
25. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
26. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides.
Fujimura T; Okuyama R; Ito Y; Aiba S
Br J Dermatol; 2008 Jun; 158(6):1256-63. PubMed ID: 18363755
[TBL] [Abstract][Full Text] [Related]
27. Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and Sezary syndrome.
Meissner K; Löning T; Rehpenning W
In Vivo; 1993; 7(3):277-80. PubMed ID: 8357970
[TBL] [Abstract][Full Text] [Related]
28. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation.
Roberts AA; Amano M; Felten C; Galvan M; Sulur G; Pinter-Brown L; Dobbeling U; Burg G; Said J; Baum LG
Mod Pathol; 2003 Jun; 16(6):543-51. PubMed ID: 12808059
[TBL] [Abstract][Full Text] [Related]
29. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.
Krejsgaard T; Odum N; Geisler C; Wasik MA; Woetmann A
Leukemia; 2012 Mar; 26(3):424-32. PubMed ID: 21904385
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the IL-31 pathway in Mycosis fungoides and Sézary syndrome.
Möbs M; Gryzik S; Haidar A; Humme D; Beyer M; Vandersee S
Arch Dermatol Res; 2015 Aug; 307(6):479-85. PubMed ID: 25488078
[TBL] [Abstract][Full Text] [Related]
32. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: search for recurrent chromosome abnormalities.
Batista DA; Vonderheid EC; Hawkins A; Morsberger L; Long P; Murphy KM; Griffin CA
Genes Chromosomes Cancer; 2006 Apr; 45(4):383-91. PubMed ID: 16382449
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma and mycosis fungoides in the same patient: clinical, immunologic, and molecular studies.
Gernone A; Frassanito MA; Pellegrino A; Vacca A; Dammacco F
Ann Hematol; 2002 Jun; 81(6):326-31. PubMed ID: 12107563
[TBL] [Abstract][Full Text] [Related]
34. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
[TBL] [Abstract][Full Text] [Related]
35. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.
Goswami M; Duvic M; Dougherty A; Ni X
J Cutan Pathol; 2012 May; 39(5):500-7. PubMed ID: 22515221
[TBL] [Abstract][Full Text] [Related]
36. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo.
Prince HM; Duvic M; Martin A; Sterry W; Assaf C; Straus DJ
J Am Acad Dermatol; 2012 Nov; 67(5):867-75. PubMed ID: 22285675
[TBL] [Abstract][Full Text] [Related]
37. [Cells in the epidermotropic lymphomas (mycosis fungoides and Sézary syndrome. Study using monoclonal antibodies].
Thivolet J; Schmitt D; Souteyrand P; Brochier J
Nouv Presse Med; 1982 Oct; 11(41):3033-8. PubMed ID: 6755391
[TBL] [Abstract][Full Text] [Related]
38. Transition of Sézary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis.
Assaf C; Hummel M; Zemlin M; Steinhoff M; Geilen CC; Stein H; Orfanos CE
J Clin Pathol; 2004 Dec; 57(12):1325-8. PubMed ID: 15563677
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease.
Lew W; Chang JY; Jung JY; Bang D
Br J Dermatol; 2008 Mar; 158(3):505-11. PubMed ID: 18205865
[TBL] [Abstract][Full Text] [Related]
40. Expression of human beta-defensins in patients with mycosis fungoides.
Gambichler T; Skrygan M; Appelhans C; Tomi NS; Reinacher-Schick A; Altmeyer P; Kreuter A
Arch Dermatol Res; 2007 Jul; 299(4):221-4. PubMed ID: 17415576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
